Sotera Health (NYSE:SHC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sotera Health (NYSE:SHC – Get Rating) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $16.83.

Several brokerages have weighed in on SHC. Wolfe Research upgraded shares of Sotera Health from a “peer perform” rating to an “outperform” rating and set a $25.00 target price on the stock in a research report on Tuesday, January 10th. The Goldman Sachs Group reduced their price target on shares of Sotera Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Wednesday, November 23rd. Royal Bank of Canada upped their price target on shares of Sotera Health from $8.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, March 1st. JPMorgan Chase & Co. raised shares of Sotera Health from an “underweight” rating to a “neutral” rating and upped their price target for the company from $6.00 to $18.00 in a report on Monday, January 23rd. Finally, Barclays raised shares of Sotera Health from an “underweight” rating to an “overweight” rating and upped their price target for the company from $6.00 to $22.00 in a report on Tuesday, January 10th.

Sotera Health Trading Up 2.5 %

Shares of SHC opened at $17.84 on Monday. The company has a current ratio of 0.81, a quick ratio of 2.74 and a debt-to-equity ratio of 5.15. The firm’s 50-day moving average is $15.41 and its two-hundred day moving average is $11.74. Sotera Health has a twelve month low of $5.78 and a twelve month high of $24.90. The firm has a market capitalization of $5.04 billion, a P/E ratio of -21.49 and a beta of 2.09.

Hedge Funds Weigh In On Sotera Health

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Sotera Health by 7.6% during the first quarter. BlackRock Inc. now owns 6,252,520 shares of the company’s stock valued at $135,429,000 after buying an additional 439,762 shares during the period. AQR Capital Management LLC lifted its stake in shares of Sotera Health by 402.0% during the fourth quarter. AQR Capital Management LLC now owns 3,477,868 shares of the company’s stock valued at $28,275,000 after buying an additional 2,785,022 shares during the period. Boston Partners lifted its stake in shares of Sotera Health by 243.2% during the third quarter. Boston Partners now owns 3,109,343 shares of the company’s stock valued at $20,997,000 after buying an additional 2,203,400 shares during the period. ArrowMark Colorado Holdings LLC lifted its stake in shares of Sotera Health by 9.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 3,048,472 shares of the company’s stock valued at $25,394,000 after buying an additional 261,675 shares during the period. Finally, State Street Corp lifted its stake in shares of Sotera Health by 1.8% during the third quarter. State Street Corp now owns 2,562,979 shares of the company’s stock valued at $17,480,000 after buying an additional 44,230 shares during the period. Hedge funds and other institutional investors own 87.21% of the company’s stock.

Sotera Health Company Profile

(Get Rating)

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries.